Innovative Medicine
-
Johnson & Johnson presents new data at IMS 2026 highlighting its industry-leading multiple myeloma portfolio, with the goal of advancing the potential for cure
· 35+ abstracts demonstrate new findings across DARZALEX®, TECVAYLI® plus DARZALEX FASPRO®, CARVYKTI®, TALVEY®, and the investigational trispecific antibody ramantamig, highlighting the potential of early intervention with immune-based therapies to transform outcomes across the patient journey · With decades of leadership in multiple myeloma, Johnson & Johnson continues to drive innovation throughout the patient journey, from market-leading backbone therapies to next-generation immune-based approaches -
Johnson & Johnson spotlights new neuropsychiatry data across bipolar mania, depression and schizophrenia at Psych Congress 2026
First presentation of pivotal Phase 3 CAPLYTA® data in adults with bipolar mania underscores the asset’s potential across mood disorders New SPRAVATO® analyses and schizophrenia research emphasize a focus on complex, high-burden neuropsychiatric conditions -
FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients
· IMAAVY is an immunoselective FcRn blocker designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies while also preserving B-cell function · Warm autoimmune hemolytic anemia is a rare, life-threatening disease in which autoantibodies cause the destruction of red blood cells, leading to severe anemia and debilitating fatigue · The approval is based on the pivotal Phase 2/3 study which demonstrated durable hemoglobin responsea · A mean increase in hemoglobin of 1 g/dL at Week 1b and improvement in FACIT-Fatiguec score at Week 24 were observed in IMAAVY-treated patientsd -
Johnson & Johnson’s RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer
Priority Review reinforces the significant potential of subcutaneous amivantamab in recurrent or metastatic head and neck cancer, where the current five-year survival rate is only 15 percent Patients achieved rapid, deep and durable responses, including a 42 percent overall response rate with one-third achieving a complete response Subcutaneous amivantamab is the only therapy in head and neck cancer engineered to target both EGFR and MET, proven drivers of tumor growth and treatment resistance -
-
-
TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma
· Investigational MonumenTAL-6 trial is the first and only Phase 3 study of a dual antigen, BCMA and GPRC5D targeting regimen in relapsed/refractory multiple myeloma · Fifth positive Phase 3 study evaluating Johnson & Johnson’s multiple myeloma T-cell therapy portfolio in second line, further strengthening the company’s leadership and commitment to advancing immunotherapy-based regimens earlier in the treatment journey -
-
IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies
· Patients in the IMAAVY 30 mg/kg treatment groupa achieved statistically significant durable hemoglobin responseb, with mean hemoglobin improvement of at least 1 g/dL as early as Week 1c · More patients treated with IMAAVY experienced improvement in fatigued and corticosteroid dose reductionse · IMAAVY is designed to target pathogenic immunoglobulin G (IgG) autoantibodies in warm autoimmune hemolytic anemia while preserving immune function · Pivotal results will be presented at EHA 2026